2025-09-05 東京科学大学
図.統合型グリコ・ナノワクチン(iGN)によるがん免疫の活性化
<関連情報>
- https://www.isct.ac.jp/ja/news/dnhcwod5uz07
- https://www.isct.ac.jp/plugins/cms/component_download_file.php?type=2&pageId=&contentsId=1&contentsDataId=2208&prevId=&key=31cec0296522cc99dec46ed57744e2a6.pdf
- https://www.nature.com/articles/s43856-025-01102-3
統合型糖質ナノワクチン技術を活用したがん免疫療法の強化 Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy
Mayumi Niimura,Yasuhisa Sakamoto,Mayuko Shimoda,Narumi Harada,Ayato Maeda,Shiho Wada,Koki Murata,Chanida Thinyakul,Saisai Liu,Haruka Ohara,Asuka Iwamoto,Yohei Kanamori,Akihiro Nita,Masahiro Wakao,Yasuo Suda,Hiroyuki Oshiumi,Tomoko Hayashi,Dennis A. Carson,Hiroyuki Shinchi & Toshiro Moroishi
Communications Medicine Published:29 August 2025
DOI:https://doi.org/10.1038/s43856-025-01102-3
Abstract
Background
Cancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. Nanoparticles have potential in cancer treatment because they offer advantages such as biocompatibility, greater stability, and precise targeting capabilities.
Method
We synthesized an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 (TLR7) ligand, sugar chains, and peptide antigens for cancer immunotherapy. The potential of iGN was investigated using a therapeutic animal model.
Results
In murine models, iGN effectively induces antigen-specific cytotoxic T cells, demonstrating prophylactic and therapeutic efficacy against tumor growth. iGN stimulates antigen-presenting cells via the TLR7–MYD88 pathway, enhancing antigen presentation and priming of cytotoxic T cells. Combination therapy with iGN and anti-PD-1 antibodies improves survival of tumor-bearing mice.
Conclusions
These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.
Plain language summary
Cancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. To address this issue, we developed integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with an antigen (target) and an adjuvant (increases potency), and evaluated its potential using a tumor-bearing mouse model. iGN therapy alone reduced tumor growth, and combinating this therapy with immunotherapy (anti-PD-1 antibodies) improved the survival of tumor-bearing mice. These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.
